二、请说明国有股东办理国有股标识进展情况。 三、请结合你公司及下属公司经营范围涉及"细胞技术研发和应用"，以及主营业务关于"开发在DNA或 RNA层面调控致病基因的候选药物"等表述，说明你公司及下属公司经营范围、实际业务是否涉及"人体 干细胞、基因诊断与治疗技术开发和应用"或其他外商投资准入限制或禁止领域及相关判断依据，本次 发行上市前后是否持续符合外商投资准入政策要求。 四、请说明前期A股上市辅导备案的具体情况，是否计划继续推进A股上市及具体安排，是否存在对本 次发行上市产生重大影响的情形。 智通财经APP获悉，9月12日，中国证监会公布《境外发行上市备案补充材料要求(2025年9月5日—2025 年9月11日)》。其中，证监会要求景泽生物补充说明最近12个月内新增股东入股原因等事项。据悉，景 泽生物已于2025年6月27日向港交所主板提交上市申请，中金公司、国元国际为联席保荐人。 证监会请景泽生物补充说明以下事项，请律师核查并出具明确的法律意见： 一、请说明最近12个月内新增股东入股原因、入股价格合理性，该等入股价格之间存在差异的原因，是 否存在入股对价异常、利益输送等情形。 五、请说明本次拟参与"全流通 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional information from Jingze Biotech regarding its recent shareholder changes and compliance with foreign investment policies as part of its listing application process [1][2]. Group 1: Regulatory Requirements - CSRC requires Jingze Biotech to explain the reasons for new shareholders joining in the last 12 months and the rationale behind the share prices, including any discrepancies and potential issues of abnormal pricing or benefit transfer [1] - The company must clarify the progress of state-owned shareholders in handling state-owned stock identification [1] - Jingze Biotech is asked to confirm whether its business scope, particularly in "cell technology research and application" and "developing candidate drugs that regulate pathogenic genes at the DNA or RNA level," involves any areas restricted or prohibited for foreign investment [1] Group 2: Company Overview - Jingze Biotech focuses on high-growth sectors of assisted reproductive drugs and ophthalmic drugs, addressing unmet clinical needs with a comprehensive R&D system and commercial-scale production capabilities [2] - The company has developed multiple product pipelines and advanced several high-tech, commercially promising drugs to late-stage clinical and commercialization phases [2]

Group 1 - The company's stock closed at 5.58 yuan on August 5, down 0.36% from the previous trading day [1] - The trading volume reached 915 million yuan with a total of 1.5753 million hands traded, and the stock experienced a volatility of 10.54% [1] - The company operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of anti-infection drugs and specialized medications [1] Group 2 - The company is registered in Chongqing and has a product line that includes innovative drugs and assisted reproductive technologies [1] - On August 5, there was a net outflow of 53.45 million yuan in main funds, with a cumulative net outflow of 31.66 million yuan over the past five trading days [1] - The stock experienced a rapid decline in the early trading session, with a drop of over 2% within five minutes [1]